

Status of implementation of SAGE interim recommendations

Abdourahamane Diallo
WHO Health Emergencies Programme



Cases of EVD with rings defined, ongoing or pending North Kivu, South Kivu and Ituri, DRC

10 October 2019

From the start of the outbreak


3091 EVD cases confirmed

2800 (90%) EVD cases with a ring defined and vaccinated

Within the last 21 days


73 EVD cases confirmed

68 (93.2%) EVD cases with rings defined and vaccinated



For rVSV-ZEBOV-GP


10 October 2019



The teams continue to vaccinate with rVSV ZEBOV GP (with informed consent) a large number of people at risk in the context of the outbreak

Data as of October 07 2019


Total consented and vaccinated




Those vaccinated included the following populations:

HCWs/FLWS	50'072	21.3%
Children 6-11 months	1'284	0.5%
Children 1-17 year old	76'245	32.4%
Pregnant women	940	0.4%
Breastfeeding Women	4'700	1.9%
Other groups	133'241	56.6%

Number of HCWs/FLWs vaccinated because they are working in affected areas (but outside rings), DRC 2018-2019



Current recommendations for rVSV-ZEBOV-GP use



**Approx
130
people**

Rings

contacts and contacts of contacts and HCWs and FLWs in affected Aires de Santé


Higher risk of Ebola

AR= 0.01% for people in vaccinated rings
AR= 0.5% for people in unvaccinated rings

Vaccine

rVSV-ZEBOV-GP

Dose = same as in RCT Guinea



**Approx
100
people**

Potential contacts

Those who can potentially be involved in the 3ry generation of cases

Low risk of Ebola

Vaccine

rVSV-ZEBOV-GP

Dose = half dose from RCT Guinea

This is the only SAGE recommendation not implemented in DRC




**World Health
Organization**

GENCIES
programme

Adjust the protocol for RVSV-ZEBOV GP while complying with Good Clinical Practice guidelines

19 October 2019



INVESTIGATION



RING DEFINITION



Collective information of the ICF contents

10 October 2019

Individual signing of ICF



PREGNANT WOMAN VACCINATION



LACTATING WOMAN VACCINATION



INFANT BELOW 1 YEAR VACCINATION






Ring vaccination


10 October 2019

Pop-up vaccination with rVSV ZEBOV GP

Temporary location where security to the teams is provided



Community leaders support and community engagement



The teams have been able to start or complete the vaccination around **587** cases by using the Pop-Up vaccination strategy.

at a distance from the residence of the contacts, often a health facility)



Ring vaccination

Targeted geographic vaccination with rVSV ZEBOV GP

10 October 2019

4 targeted geographical vaccination done:

Z200 -Butanuka in Beni - 18 to 20/10/2018

200 participants vaccinated (73 contacts and 127 contacts of contacts).

Z201 Kanyihunga in Kalunguta - 07 to 16/11/2018

655 participants vaccinated (22 contacts and 633 contacts of contacts);


Z202 Muchanga in Katwa -- 16/04/2019 to 16/05/2019 758 participants vaccinated (88 contacts and 670 contacts of contacts).

Z203 Wayene in Katwa -- 15/04/2019 to 03/05/2019

567 participants vaccinated (127 contacts and 440 contacts of contacts).

All the contacts and contacts of contacts of all cases reported in a given village or Aire de Santé are enumerated and invited for vaccination simultaneously.

ation where security
ms is provided






Ring vaccination

Adjusted strategies to the local context

10 October 2019



Mop up operations:

Fixed team in a location

Search all missed contacts
and contacts of contacts:

- 1st for cases in last 10 days
- 2nd for cases in last 21 days

More than 40 cases



World Health
Organization


HEALTH
EMERGENCIES
programme



Ring vaccination

Adjusted strategies to the local context

10 October 2019



**Several teams
working on one case:**
Vaccinating simultaneously
at all places visited by the
case since onset of Sxs
(satellites)

More than 10 cases



World Health
Organization


HEALTH
EMERGENCIES
programme



Ring vaccination

Adjusted strategies to the local context

10 October 2019



Including people at risk around community deaths or probable cases:

Vaccinating simultaneously as part of an existing ring

More than 10 cases



World Health
Organization


HEALTH
EMERGENCIES
programme

Adjust the protocol for RVSV-ZEBOV GP while complying with Good Clinical Practice guidelines

10 October 2019



6. 30 minutes follow up



7. Scheduled follow up visits

For all vaccinees
No scheduled safety monitoring visits

For infants 6-11 mo
One follow-up visit at Day 21 post vaccination

For pregnant women
2nd and 3rd trimester
Day 21 post vaccination
Delivery or end of pregnancy visit

8. Passive monitoring of SAEs

- 1.results in death,
- 2.is life-threatening
- 3.requires inpatient hospitalization or causes prolongation of existing hospitalization
- 4.results in persistent or significant disability/incapacity,
- 5.may have caused a congenital anomaly/birth defect, or
- 6.requires intervention to prevent permanent impairment or damage







36 teams (3 teams from MSF since Sept 2019)

- 400 Congolese trained in GCP and **protocol SOPs**
- 45 initially, now 25 Guinean researchers providing training and critical Q/A support



October 10, 2019



Use rVSV-ZEBOV-GP



Potential contacts

Persons who can potentially be involved in the tertiary generation of cases

**Living in affected areas and +
living in neighboring areas**

**Not eligible for rVSV-ZEBOV GP
+ at a lower risk than those in the
rings**

**Janssen Ad26.ZEBOV –
MVA-BN-FILO**



Contacts

Contacts of contacts



World
Organiza

EMERGENCIES
programme

Ad26.ZEBOV/MVA-BN-Filo study in DRC

- Open-label non-randomised design
- Study vaccine: Ad26.ZEBOV/MVA-BN-Filo
- Vaccination schedule: two-dose schedule +/- 56 days apart
- Study population: targeted at-risk populations adults and children aged 1 yo+
- in areas that do not have active Ebola transmission (500,000 participants)
- Pis: INRB, LSHTM
- Study objectives:
 - Safety and immunogenicity
 - Qualitative assessment of EVD knowledge and perception and attitudes towards the vaccine

Current status:

Study being approved,
field preparations
ongoing

ZEBOVAC clinical trial in Uganda

- An open-label single arm phase II study sponsored by UVRI/LSHTM
- Study vaccine: Ad26.ZEBOV/MVA-BN-Filo
- Vaccination schedule: two-dose schedule +/- 56 days apart
- Study population: Frontline and healthcare workers (FLWs/HCWs, up to 800 participants)
- Study objectives:
 - Safety and immunogenicity
 - Qualitative assessment of EVD knowledge and perception and attitudes towards the vaccine among FLWs/HCWs

Current status:

Study currently recruiting
Over 200 volunteers
enrolled, 4 having
received the booster dose

Regional preparedness for deployment of yet to be licensed Ebola Vaccines & Therapeutics

Country	WHO provided protocols and evidence for rVSV-ZEBOV-GP and experimental therapeutics	Principal Investigator nominated	Import authorization		Vaccination HCWs/FLWs	Amended rVSV-ZEBOV-GP Protocol approved by NRA and ERC	Therapeutics(2) protocol approved by NRA and ERC
			rVSV-ZEBOV-GP	Experimental Therapeutics (2)			
South Sudan	Done	Done	Done	Ongoing	Ongoing	Ongoing	Ongoing
Rwanda	Done	Done	Done	Ongoing	Ongoing	Done	Submitted
Uganda	Done	Done	Done	Done	Ongoing	Done	Submitted
Burundi	Done	Done	Done	Planned	Ongoing	Done	Planned
Tanzania	Done	Done	Submitted	Submitted	Risk dependent	Done	Submitted
Zambia	Done	Ongoing	Ongoing	Ongoing	Risk dependent	Planned	Planned
Angola	Done	Ongoing	Ongoing	Ongoing	Risk dependent	Ongoing	Ongoing
Congo Brazzaville	Done	Ongoing	Ongoing	Ongoing	Risk dependent	Planned	Planned
CAR	Done	Ongoing	Ongoing	Ongoing	Risk dependent	Planned	Planned
Kenya*	Done	Done	Ongoing	Ongoing	Risk dependent	Ongoing	Ongoing

HCWs/FLWs vaccinated **in bordering areas at high-risk** of spread as per SAGE recommendations

10 October 2019

Bunia

2.217 HCWs /FLWs vaccinated

South Sudan

2.793 HCWs /FLWs vaccinated

Uganda

6.805 HCWs /FLWs vaccinated

Goma

9.213 HCWs /FLWs vaccinated

Rwanda

2.874 HCWs /FLWs vaccinated

Burundi

3.524 HCWs /FLWs vaccinated



World Health
Organization

Vaccination in DRC is going on in the context of challenging circumstances

October 2019



Vaccination in DRC is going on in the context of challenging circumstances

